Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 1997 Mar;136(3):415-20
Date
03/01/1997Pubmed ID
9115929DOI
10.1111/j.1365-2133.1997.tb14957.xScopus ID
2-s2.0-0031057403 (requires institutional sign-in at Scopus site) 62 CitationsAbstract
Treatment of epidermolysis bullosa acquisita (EBA) with conventional therapy frequently does not result in improvement. Extracorporeal photochemotherapy (ECP) is a novel immunomodulating technique which might be of benefit in the treatment of autoimmune disease. We prospectively studied three patients with refractory EBA who were treated with ECP. All three patients had improvement in objective measurement of their disease severity while two of the three had significant subjective improvement in their skin fragility and the clinical activity of their disease. Both the objective and subjective manifestations of the disease continued to improve 6 months after completion of the protocol. ECP may be therapeutic option in the treatment of patients with EBA who are refractory to conventional therapy.
Author List
Gordon KB, Chan LS, Woodley DTAuthor
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgedAutoantibodies
Autoimmune Diseases
Basement Membrane
Epidermolysis Bullosa Acquisita
Female
Fluorescent Antibody Technique, Indirect
Humans
Male
Middle Aged
Photopheresis
Prospective Studies
Skin
